BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biogen, Inc. (Massachusetts) (BGEN) And IDEC Pharmaceuticals Corporation (IDPH) To Make Presentation At Credit Suisse First Boston Healthcare Conference


10/19/2005 5:10:32 PM

CAMBRIDGE, Mass., and SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Biogen, Inc. and IDEC Pharmaceuticals Corporation announced today that IDEC's Chairman and Chief Executive Officer, William H. Rastetter, Ph.D., and Biogen's Chief Financial Officer, Peter Kellogg, will make a presentation at the Credit Suisse First Boston Healthcare Conference on Thursday, November 13, 2003 at 9:00 a.m. Mountain Time (MT) at The Arizona Biltmore Resort in Phoenix, Arizona.

(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )

Assuming the merger between IDEC and Biogen is approved by shareholders at Special Meetings on Wednesday, November 12, held in San Diego and Cambridge, respectively, Mr. Rastetter and Mr. Kellogg would give a presentation about the new Biogen Idec.

The presentation will be webcast live and is accessible by using the link provided in the investor relations section of Biogen's (http://www.biogen.com/) and IDEC's (http://www.idecpharm.com/) websites.

About Biogen

Biogen is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities.

About IDEC Pharmaceuticals

IDEC is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin(R)) approved in the United States, which is used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and, with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan(R)) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.

Contact: Rob Jacobson Investor Relations Specialist Biogen, Inc. 617/679-3710

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, 888-776-6555 or 212-782-2840 Biogen, Inc.

CONTACT: Rob Jacobson, Investor Relations Specialist of Biogen,+1-617-679-3710



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES